Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ana‐Rita Pedrosa
Observed names:
Ana Rita Pedrosa,
Ana-Rita Pedrosa
Institutions:
Queen Mary University of London,
Barts Cancer Institute
Observed institutions:
University of Lisbon,
Queen Mary University of London,
Juntendo University,
Centro de Investigação Interdisciplinar em Sanidade Animal,
Universidade Técnica de Lisboa,
Barts Cancer Institute
show all 6
ORCID:
0000-0002-4421-6968
Observed ORCID:
0000-0002-4421-6968
OpenAlex ID:
A5028885785
Works
47
Awards
4
Endothelial Jagged1 Antagonizes Dll4 Regulation of Endothelial Branching and Promotes Vascular Maturation Downstream of Dll4/Notch1
2015
·
Ana-Rita Pedrosa
, Alexandre Trindade
, et al.
·
Arteriosclerosis Thrombosis and Vascular Biology
·
152
Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth
2020
·
Tanguy Lechertier
, Louise E. Reynolds
, et al.
·
Nature Communications
·
75
PDF
Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions
2015
·
Ana-Rita Pedrosa
, Alexandre Trindade
, et al.
·
Oncotarget
·
67
PDF
Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861
2019
·
Ana-Rita Pedrosa
, Natalia Bodrug
, et al.
·
Cancer Research
·
61
PDF
Effects of senescence on the tumour microenvironment and response to therapy
2023
·
Louise E. Reynolds
, Seynab Maallin
, et al.
·
FEBS Journal
·
45
PDF
Low-Dosage Inhibition of Dll4 Signaling Promotes Wound Healing by Inducing Functional Neo-Angiogenesis
2012
·
Alexandre Trindade
, Dusan Djokovic
, et al.
·
PLoS ONE
·
40
PDF
Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development
2015
·
Ana‐Rita Pedrosa
, José L. Graça
, et al.
·
The Prostate
·
29
Improved Immunotherapy Efficacy by Vascular Modulation
2021
·
Emma L. Newport
, Ana Rita Pedrosa
, et al.
·
Cancers
·
21
PDF
Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression
2021
·
Delphine M. Lees
, Louise E. Reynolds
, et al.
·
Angiogenesis
·
21
PDF
“Splitting the matrix”: intussusceptive angiogenesis meets MT1‐MMP
2019
·
Gabriela D'Amico
, José M Muñoz‐Félix
, et al.
·
EMBO Molecular Medicine
·
21
PDF
Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth
2021
·
Emma Newport
, Ana Rita Pedrosa
, et al.
·
The Journal of Pathology
·
19
Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2022
·
Ganga Gopinathan
, Chiara Berlato
, et al.
·
Molecular Cancer Therapeutics
·
10
PDF
Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential
2025
·
Ana‐Rita Pedrosa
, Alejandro Castillo‐Kauil
, et al.
·
The Journal of Pathology
·
3
Author Correction: Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth
2023
·
Tanguy Lechertier
, Louise E. Reynolds
, et al.
·
Nature Communications
·
2
PDF
Correction to: Phosphorylation of pericyte FAK‑Y861 affects tumour cell apoptosis and tumour blood vessel regression
2021
·
Delphine M. Lees
, Louise E. Reynolds
, et al.
·
Angiogenesis
·
2
PDF
Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden
2026
·
Madeleine Benguigui
, Abby Lockwood
, et al.
·
Research Square
PDF
The Angiocrine Niche in Cancer Therapy Responses: The Role of Vascular Endothelial Cells in Immunomodulation
2026
·
Abby Lockwood
, Madeleine Benguigui
, et al.
·
Annual Review of Cancer Biology
Figure 5 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Figure 2 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Figure 3 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Figure 4 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Figure 1 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Figure 6 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Data from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2023
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Supplementary Table from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2023
·
Ganga Gopinathan
, Chiara Berlato
, et al.
Show more works
View as search
Works count:
47
Citation count:
568
H-index:
11
I10-index:
12
Year
Topic
Type